Johnson & Johnson Advances Seltorexant in Major Depressive Disorder

Johnson & Johnson (JNJ) is advancing its pipeline of treatments for major depressive disorder, including seltorexant. The company has also signed a multi-year agreement to expand access to advanced cardiac electrophysiology technologies in ambulatory surgery centers. This move highlights fresh momentum across both J&J's pharmaceutical and MedTech operations.

J&J is one of the largest global healthcare companies, with a market cap of US$630.9 billion. The R&D updates sit within a broad portfolio that spans treatments and technologies used in many parts of the healthcare system worldwide.

Investors are likely looking for clear milestones, such as additional late-stage data or regulatory decisions for seltorexant and other neuroscience assets. They may also look for evidence that the ACCESS electrophysiology agreement is contributing to procedure volumes.